Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials.


Journal Article

Clevidipine is an arterial, selective, dihydropyridine calcium channel blocker with an ultrashort half-life. In this prospective, randomized, open-label, parallel-comparison trial series, the safety and efficacy of intravenous clevidipine with nitroglycerin, sodium nitroprusside and nicardipine in hypertensive patients during cardiac surgery were compared. No differences in the incidences of myocardial infarction, stroke or renal dysfunction were observed between treatment groups. Mortality was similar between the clevidipine-nitrogylcerine- and clevidipine-nicardipine-treated groups, whereas mortality appeared to be greater in the sodium nitroprusside group compared to clevidipine (p = 0.04 in a univariant analysis). Clevidipine was significantly more effective in blood pressure control compared with nitroglycerin (p = 0.0006) or sodium nitroprusside (p = 0.003) and was associated with fewer blood pressure excursions compared with nicardipine as a predetermined blood pressure range was narrowed.

Full Text

Duke Authors

Cited Authors

  • Aronson, S

Published Date

  • May 2009

Published In

Volume / Issue

  • 7 / 5

Start / End Page

  • 465 - 472

PubMed ID

  • 19419254

Pubmed Central ID

  • 19419254

Electronic International Standard Serial Number (EISSN)

  • 1744-8344

Digital Object Identifier (DOI)

  • 10.1586/erc.09.1


  • eng

Conference Location

  • England